Targeting miR-21 to treat psoriasis

Science Translational Medicine

Volumn 6, Issue 225, 2014, Pages

  Guinea Viniegra, Juan ^a   Jiménez, María ^a   Schonthaler, Helia B ^a   Navarro, Raquel ^b   Delgado, Yolanda ^b   Concha Garzón, María José ^b   Tschachler, Erwin ^c   Obad, Susanna ^d   Daudén, Esteban ^b   Wagner, Erwin F ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c Universitatsklinik fur Dermatologie   (Austria)

^d Santaris Pharma AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INTERLEUKIN 6; LOCKED NUCLEIC ACID; MICRORNA 21; PROTEIN C JUN; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR JUNB; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; UPREGULATION;

ADAM PROTEINS; ANIMALS; BIOPSY; CASE-CONTROL STUDIES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; GENE TARGETING; GENETIC THERAPY; HUMANS; INTERLEUKIN-6; MALE; MICE; MICE, KNOCKOUT; MICRORNAS; OLIGONUCLEOTIDES; PSORIASIS; SKIN; SKIN TRANSPLANTATION; STAT3 TRANSCRIPTION FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 84896336919     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008089     Document Type: Article

References (33)

1. M. A. Lowes, A. M. Bowcock, J. G. Krueger, Pathogenesis and therapy of psoriasis. Nature 445, 866-873 (2007).
2. J. T. Elder, A. T. Bruce, J. E. Gudjonsson, A. Johnston, P. E. Stuart, T. Tejasvi, J. J. Voorhees, G. R. Abecasis, R. P. Nair, Molecular dissection of psoriasis: Integrating genetics and biology. J. Invest. Dermatol. 130, 1213-1226 (2010).
3. P. M. Laws, H. S. Young, Current and emerging systemic treatment strategies for psoriasis. Drugs 72, 1867-1880 (2012).
4. F. O. Nestle, D. H. Kaplan, J. Barker, Psoriasis. N. Engl. J. Med. 361, 496-509 (2009).
5. E. F. Wagner, H. B. Schonthaler, J. Guinea-Viniegra, E. Tschachler, Psoriasis: What we have learned from mouse models. Nat. Rev. Rheumatol. 6, 704-714 (2010).
6. M. A. Lowes, C. B. Russell, D. A. Martin, J. E. Towne, J. G. Krueger, The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 34, 174-181 (2013).
7. J. Guinea-Viniegra, R. Zenz, H. Scheuch, D. Hnisz, M. Holcmann, L. Bakiri, H. B. Schonthaler, M. Sibilia, E. F. Wagner, TNFα shedding and epidermal inflammation are controlled by Jun proteins. Genes Dev. 23, 2663-2674 (2009).
8. J. R. Zibert, M. B. Løvendorf, T. Litman, J. Olsen, B. Kaczkowski, L. Skov, MicroRNAs and potential target interactions in psoriasis. J. Dermatol. Sci. 58, 177-185 (2010).
9. G. Girolomoni, G. Altomare, F. Ayala, E. Berardesca, P. Calzavara-Pinton, S. Chimenti, A. Peserico, A. Puglisi Guerra, G. A. Vena, Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacol. Immunotoxicol. 34, 548-560 (2012).
10. M. Esteller, Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861-874 (2011).
11. H. L. Janssen, H. W. Reesink, E. J. Lawitz, S. Zeuzem,M. Rodriguez-Torres, K. Patel, A. J. van derMeer, A. K. Patick, A. Chen, Y. Zhou, R. Persson, B. D. King, S. Kauppinen, A. A. Levin, M. R. Hodges, Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685-1694 (2013).
12. A. Ichihara, M. Jinnin, K. Yamane, A. Fujisawa, K. Sakai, S. Masuguchi, S. Fukushima, K. Maruo, H. Ihn, microRNA-mediated keratinocyte hyperproliferation in psoriasis vulgaris. Br. J. Dermatol. 165, 1003-1010 (2011).
13. C. E. Joyce, X. Zhou, J. Xia, C. Ryan, B. Thrash, A. Menter, W. Zhang, A. M. Bowcock, Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum. Mol. Genet. 20, 4025-4040 (2011).
14. E. Sonkoly, T. Wei, P. C. Janson, A. Sääf, L. Lundeberg, M. Tengvall-Linder, G. Norstedt, H. Alenius, B. Homey, A. Scheynius, M. Ståhle, A. Pivarcsi, MicroRNAs: Novel regulators involved in the pathogenesis of psoriasis? PLOS One 2, e610 (2007).
15. F. Meisgen, N. Xu, T. Wei, P. C. Janson, S. Obad, O. Broom, N. Nagy, S. Kauppinen, L. Kemény, M. Ståhle, A. Pivarcsi, E. Sonkoly, MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp. Dermatol. 21, 312-314 (2012).
16. M. R. Schneider, MicroRNAs as novel players in skin development, homeostasis and disease. Br. J. Dermatol. 166, 22-28 (2012).
17. F. M. Selaru, A. V. Olaru, T. Kan, S. David, Y. Cheng, Y. Mori, J. Yang, B. Paun, Z. Jin, R. Agarwal, J. P. Hamilton, J. Abraham, C. Georgiades, H. Alvarez, P. Vivekanandan, W. Yu, A. Maitra, M. Torbenson, P. J. Thuluvath, G. J. Gores, N. F. LaRusso, R. Hruban, S. J. Meltzer, MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49, 1595-1601 (2009).
18. B. Wang, S. H. Hsu, S. Majumder, H. Kutay, W. Huang, S. T. Jacob, K. Ghoshal, TGFβ-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 29, 1787-1797 (2010).
19. H. B. Schonthaler, R. Huggenberger, S. K. Wculek, M. Detmar, E. F. Wagner, Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc. Natl. Acad. Sci. U.S.A. 106, 21264-21269 (2009).
20. R. Zenz, R. Eferl, L. Kenner, L. Florin, L. Hummerich, D. Mehic, H. Scheuch, P. Angel, E. Tschachler, E. F. Wagner, Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437, 369-375 (2005).
21. D. Iliopoulos, S. A. Jaeger, H. A. Hirsch, M. L. Bulyk, K. Struhl, STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 39, 493-506 (2010).
22. A. S. Haider, J. Duculan, J. A. Whynot, J. G. Krueger, Increased JunB mRNA and protein expression in psoriasis vulgaris lesions. J. Invest. Dermatol. 126, 912-914 (2006).
23. S. Obad, C. O. dos Santos, A. Petri, M. Heidenblad, O. Broom, C. Ruse, C. Fu, M. Lindow, J. Stenvang, E. M. Straarup, H. F. Hansen, T. Koch, D. Pappin, G. J. Hannon, S. Kauppinen, Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43, 371-378 (2011).
24. X. Ma, M. Kumar, S. N. Choudhury, L. E. Becker Buscaglia, J. R. Barker, K. Kanakamedala, M. F. Liu, Y. Li, Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 108, 10144-10149 (2011).
25. B. J. Nickoloff, S. L. Kunkel, M. Burdick, R. M. Strieter, Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am. J. Pathol. 146, 580-588 (1995).
26. C. L. Leonardi, J. L. Powers, R. T. Matheson, B. S. Goffe, R. Zitnik, A. Wang, A. B. Gottlieb; Etanercept Psoriasis Study Group, Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022 (2003).
27. E. D. Roberson, A. M. Bowcock, Psoriasis genetics: Breaking the barrier. Trends Genet. 26, 415-423 (2010).
28. X. Gu, E. Nylander, P. J. Coates, K. Nylander, Effect of narrow-band ultraviolet B phototherapy on p63 and microRNA (miR-21 and miR-125b) expression in psoriatic epidermis. Acta Derm. Venereol. 91, 392-397 (2011).
29. U. Agrawal, M. Gupta, D. Dube, S. P. Vyas, Options and opportunities for clinical management and treatment of psoriasis. Crit. Rev. Ther. Drug Carrier Syst. 30, 51-90 (2013).
30. M. E. Hatley, D. M. Patrick, M. R. Garcia, J. A. Richardson, R. Bassel-Duby, E. van Rooij, E. N. Olson, Modulation of K-Ras-dependent lung tumorigenesis by microRNA-21. Cancer Cell 18, 282-293 (2010).
31. P. P. Medina, M. Nolde, F. J. Slack, OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467, 86-90 (2010).
32. F. Atzeni, R. Talotta, F. Salaffi, A. Cassinotti, V. Varisco, M. Battellino, S. Ardizzone, F. Pace, P. Sarzi-Puttini, Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun. Rev. 12, 703-708 (2013).
33. B. Mansouri, M. Patel, A. Menter, Biological therapies for psoriasis. Expert Opin. Biol. Ther. 13, 1715-1730 (2013).